Group
ALK targeting TKI
The data below refer to patients treated with ALK targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.